Additionally, IgG therapies face challenges such as resistance development, limited tumor penetration, and severe immune-related adverse effects (8) (9) (10) underscoring the need for novel alternatives like IgM, which could potentially overcome these obstacles due to its distinct properties. The gene discussed is CD40LG; the disease is neoplasm.